Holen Sie sich die Stockscreener-App
1.9983
2.62%
-0.0517
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Australia
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com UK
Perspective Therapeutics (NYSE:CATX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World
Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times
Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan
Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World
Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World
HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World
Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com
Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Reports 2024 Earnings and Clinical Progress - TipRanks
Perspective Therapeutics Inc (CATX) Reports Annual EPS Loss of $1.23, Revenue at $1.5 Million, Surpassing Estimates - GuruFocus.com
Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026 - Marketscreener.com
Perspective Therapeutics Secures 2-Year Runway with $227M Cash, Advances Cancer Trials - Stock Titan
CATX stock touches 52-week low at $2.31 amid market fluctuations - Investing.com
What is HC Wainwright’s Forecast for CATX FY2025 Earnings? - Defense World
Brachytherapy Market Expected to Reach USD 1.5 Billion by 2031 | - openPR
HC Wainwright Reiterates “Buy” Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush - Defense World
Perspective Flat on New Drug Trials - Baystreet.ca
Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy - Marketscreener.com
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - Marketscreener.com
Perspective Therapeutics, Inc. Initiates First Patient Dosing in Phase 1/2a Trial of [212Pb]VMT01 for Melanoma Treatment - Nasdaq
Breakthrough Melanoma Treatment: New Alpha Therapy Combined With Opdivo Shows Promise - Stock Titan
Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register
Analysts Issue Forecasts for CATX Q4 Earnings - Defense World
HC Wainwright Initiates Coverage on Perspective Therapeutics (NYSE:CATX) - Defense World
Dyne Therapeutics Inc (DYN): A New Perspective - Stocks Register
Brookline Capital Management Estimates CATX FY2024 Earnings - The AM Reporter
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
HC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation - Nasdaq
Brokers Set Expectations for CATX FY2024 Earnings - Defense World
Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Brookline Capital Management - Defense World
Perspective Therapeutics at Barclays Healthcare: Radiopharmaceutical Innovations By Investing.com - Investing.com Canada
Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target -March 10, 2025 at 08:33 am EDT - Marketscreener.com
Rhumbline Advisers Has $303,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Scotiabank - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of “Buy” by Brokerages - Defense World
Perspective Therapeutics (NYSE:CATX) Upgraded at Lifesci Capital - Defense World
Scotiabank Initiates Coverage of Perspective Therapeutics (CATX) with Sector Outperform Recommendation - Nasdaq
Scotiabank starts Perspective Therapeutics with Sector Outperform By Investing.com - Investing.com South Africa
Scotiabank starts Perspective Therapeutics with Sector Outperform - Investing.com
Analysts Set Expectations for CATX FY2024 Earnings - Defense World
Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning - TipRanks
Y Intercept Hong Kong Ltd Invests $33,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Raised to Strong-Buy at Cantor Fitzgerald - Defense World
0.62%
0.92%
Kapitalisierung:
|
Volumen (24h):